CADTH Canadian Drug Expert Review Committee final recommendation: Adalimumab (Humira -- abbVie) indication: ulcerative colitis
The CADTH Canadian Drug Expert Committee (CDEC) recommends that adalimumab not be listed at the submitted price for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids, azathioprine,...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, 2016
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that adalimumab not be listed at the submitted price for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids, azathioprine, and/or 6-mercaptopurine or who are intolerant to such therapies |
|---|---|
| Item Description: | "Notice of Final Recommendation - April 15, 2016." |
| Physical Description: | 1 PDF file (7 pages) |